Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis

Biochemical and Biophysical Research Communications

Volumn 345, Issue 1, 2006, Pages 371-376

  Tits, Lambertus J H van ^a   Jacobs, Esther M G ^a   Swinkels, Dorine W ^a   Lemmers, Heidi L M ^a   Vleuten, Gerly M van der ^a   Graaf, Jacqueline de ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Heterozygous hemochromatosis; Lipid peroxidation; Low density lipoprotein oxidation; Non transferrin bound iron

Indexed keywords

APOLIPOPROTEIN B; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IRON; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMOCHROMATOSIS; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LIPID PEROXIDATION; MALE; OXIDATION; PRIORITY JOURNAL;

ADULT; FEMALE; HEMOCHROMATOSIS; HETEROZYGOTE; HUMANS; IRON; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; PROTEIN BINDING; TRANSFERRIN;

EID: 33646425628     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.100     Document Type: Article

References (30)

1. Danesh J., and Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99 (1999) 852-854
2. de Valk B., and Marx J.J. Iron, atherosclerosis, and ischemic heart disease. Arch. Intern. Med. 159 (1999) 1542-1548
3. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28 (2000) 1815-1826
4. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 2 Suppl 1 (1993) 118-126
5. Hershko C., and Peto T.E. Non-transferrin plasma iron. Br. J. Haematol. 66 (1987) 149-151
6. Gosriwatana I., Loreal O., Lu S., Brissot P., Porter J., and Hider R.C. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal. Biochem. 273 (1999) 212-220
7. de Valk B., Addicks M.A., Gosriwatana I., Lu S., Hider R.C., and Marx J.J. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur. J. Clin. Invest 30 (2000) 248-251
8. Roest M., van der Schouw Y.T., de V.B., Marx J.J., Tempelman M.J., de Groot P.G., Sixma J.J., and Banga J.D. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 100 (1999) 1268-1273
9. Tuomainen T.P., Kontula K., Nyyssonen K., Lakka T.A., Helio T., and Salonen J.T. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern. Finl. Circ. 100 (1999) 1274-1279
10. Derstine J.L., Murray-Kolb L.E., Yu-Poth S., Hargrove R.L., Kris-Etherton P.M., and Beard J.L. Iron status in association with cardiovascular disease risk in 3 controlled feeding studies. Am. J. Clin. Nutr. 77 (2003) 56-62
11. de Almeida S.F., Carvalho I.F., Cardoso C.S., Cordeiro J.V., Azevedo J.E., Neefjes J., and de S.M. HFE cross- talks with the MHC class I antigen presentation pathway. Blood 106 (2005) 971-977
12. Breuer W., and Cabantchik Z.I. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal. Biochem. 299 (2001) 194-202
13. Jacobs E.M., Hendriks J.C., van Tits B.L., Evans P.J., Breuer W., Liu D.Y., Jansen E.H., Jauhiainen K., Sturm B., Porter J.B., Scheiber-Mojdehkar B., von B.L., Cabantchik Z.I., Hider R.C., and Swinkels D.W. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341 (2005) 241-250
14. Demacker P.N., Hessels M., Toenhake-Dijkstra H., and Baadenhuijsen H. Precipitation methods for high- density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin. Chem. 43 (1997) 663-668
15. Lopes-Virella M.F., Virella G., Evans G., Malenkos S.B., and Colwell J.A. Immunonephelometric assay of human apolipoprotein Al. Clin. Chem. 26 (1980) 1205-1208
16. van Tits L., de Graaf J., Hak-Lemmers H., Bredie S., Demacker P., Holvoet P., and Stalenhoef A. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab. Invest. 83 (2003) 13-21
17. Holvoet P., Macy E., Landeloos M., Jones D., Nancy J.S., Van de W.F., and Tracy R.P. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin. Chem. 52 (2006) 760-764
18. van Tits L.J., De Waart F., Hak-Lemmers H.L., van Heijst P., de Graaf J., Demacker P.N., and Stalenhoef A.F. Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic. Biol. Med. 30 (2001) 1122-1129
19. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6 (1989) 67-75
20. Kleinveld H.A., Hak-Lemmers H.L., Stalenhoef A.F., and Demacker P.N. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low- density lipoprotein. Clin. Chem. 38 (1992) 2066-2072
21. de Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., and Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11 (1991) 298-306
22. Binkoski A.E., Kris-Etherton P.M., and Beard J.L. Iron supplementation does not affect the susceptibility of LDL to oxidative modification in women with low iron status. J. Nutr. 134 (2004) 99-103
23. Brouwers A., Langlois M., Delanghe J., Billiet J., De B.M., Vercaemst R., Rietzschel E., Bernard D., and Blaton V. Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis 176 (2004) 189-195
24. Iribarren C., Sempos C.T., Eckfeldt J.H., and Folsom A.R. Lack of association between ferritin level and measures of LDL oxidation: the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis 139 (1998) 189-195
25. Tuomainen T.P., Diczfalusy U., Kaikkonen J., Nyyssonen K., and Salonen J.T. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic. Biol. Med. 35 (2003) 922-928
26. van Hoydonck P.G., Schouten E.G., Hoppenbrouwers K.P., and Temme E.H. Is blood donation induced low iron status associated with favourable levels of OxLDL, s-ICAM-1, sVCAM-1 and vWF-antigen in healthy men. Atherosclerosis 172 (2004) 321-327
27. Lee D.H., and Jacobs Jr. D.R. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med. Hypotheses 62 (2004) 442-445
28. Hider R.C. Nature of nontransferrin-bound iron. Eur. J. Clin. Invest 3 Suppl. 1 (2002) 50-54
29. Salahudeen A.K., Oliver B., Bower J.D., and Roberts L.J. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 60 (2001) 1525-1531
30. Kartikasari A.E., Georgiou N.A., Visseren F.L., van Kats-Renaud H., Sweder van A.B., and Marx J.J. Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J. 20 (2006) 353-355